Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Vincent Lo Re III,Noelle Cocoros,Rebecca Hubbard,Sarah Dutcher,Craig Newcomb,John Connolly,Silvia Perez-Vilar,Dena Carbonari,Maria Kempner,José Hernández-Muñoz,Andrew Petrone,Allyson Pishko,Meighan Rogers Driscoll,James Brash,Sean Burnett,Catherine Cohet,Matthew Dahl,Terese DeFor,Antonella Delmestri,Djeneba Djibo,Talita Duarte-Salles,Laura Harrington,Melissa Kampman,Jennifer Kuntz,Xavier Kurz,Núria Mercadé-Besora,Pamala Pawloski,Peter Rijnbeek,Sarah Seager,Claudia Steiner,Katia Verhamme,Fangyun Wu,Yunping Zhou,Edward Burn,J Paterson,Daniel Prieto-Alhambra
DOI: https://doi.org/10.2147/clep.s448980
2024-02-11
Clinical Epidemiology
Abstract:Vincent Lo Re III, 1, 2, &ast Noelle M Cocoros, 3, 4, &ast Rebecca A Hubbard, 2 Sarah K Dutcher, 5 Craig W Newcomb, 2 John G Connolly, 3, 4 Silvia Perez-Vilar, 5 Dena M Carbonari, 2 Maria E Kempner, 3, 4 José J Hernández-Muñoz, 5 Andrew B Petrone, 3, 4 Allyson M Pishko, 6 Meighan E Rogers Driscoll, 3, 4 James T Brash, 7 Sean Burnett, 8, 9 Catherine Cohet, 10 Matthew Dahl, 8, 11 Terese A DeFor, 12 Antonella Delmestri, 13 Djeneba Audrey Djibo, 14 Talita Duarte-Salles, 15, 16 Laura B Harrington, 17 Melissa Kampman, 18 Jennifer L Kuntz, 19 Xavier Kurz, 10 Núria Mercadé-Besora, 15 Pamala A Pawloski, 12 Peter R Rijnbeek, 16 Sarah Seager, 7 Claudia A Steiner, 20, 21 Katia Verhamme, 16 Fangyun Wu, 8, 22 Yunping Zhou, 23 Edward Burn, 13 J Michael Paterson, 8, 22, &ast Daniel Prieto-Alhambra 13, 16, &ast 1 Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2 Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 3 Department of Population Medicine, Harvard Medical School, Boston, MA, USA; 4 Harvard Pilgrim Healthcare Institute, Boston, MA, USA; 5 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; 6 Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 7 IQVIA, Real World Solutions, Brighton, UK; 8 Canadian Network for Observational Drug Effect Studies (CNODES), Toronto, Ontario, Canada; 9 Therapeutics Initiative, University of British Columbia, Vancouver, British Columbia, Canada; 10 Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, Netherlands; 11 Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada; 12 HealthPartners Institute, Bloomington, MN, USA; 13 Pharmaco- and Device Epidemiology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK; 14 CVS Health, Blue Bell, PA, USA; 15 Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; 16 Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands; 17 Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA; 18 Health Canada, Ottawa, Ontario, Canada; 19 Kaiser Permanente Northwest Center for Health Research, Portland, OR, USA; 20 Kaiser Permanente Colorado Institute for Health Research, Aurora, CO, USA; 21 Colorado Permanente Medical Group, Denver, CO, USA; 22 ICES, Toronto, Ontario, Canada; 23 Humana Healthcare Research, Inc., Louisville, KY, USA &astThese authors contributed equally to this work Correspondence: Vincent Lo Re III, Division of Infectious Diseases, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA, Fax +1 215 573 5315, Email Purpose: Few studies have examined how the absolute risk of thromboembolism with COVID-19 has evolved over time across different countries. Researchers from the European Medicines Agency, Health Canada, and the United States (US) Food and Drug Administration established a collaboration to evaluate the absolute risk of arterial (ATE) and venous thromboembolism (VTE) in the 90 days after diagnosis of COVID-19 in the ambulatory (eg, outpatient, emergency department, nursing facility) setting from seven countries across North America (Canada, US) and Europe (England, Germany, Italy, Netherlands, and Spain) within periods before and during COVID-19 vaccine availability. Patients and Methods: We conducted cohort studies of patients initially diagnosed with COVID-19 in the ambulatory setting from the seven specified countries. Pa -Abstract Truncated-
public, environmental & occupational health